Keryx Biopharmaceuticals Receives Nasdaq No...(our actual resultsto differ materially a...)

Date:4/25/2008

our actual results to differ materially are the following: There can be no assurance that the Company will apply for inclusion on the Nasdaq Capital Market, or if so, that the Company's application for inclusion on the Nasdaq Capital Market will be approved,, or that if approved and the listing is transferred, that the Company will continue to meet the Nasdaq Capital Market listing requirements, and/or if the Company's application is denied, that the Company will satisfy Nasdaq's conditions for continued listing on the Nasdaq Global Market, that any potential appeal or hearing for a stay of delisting from the Nasdaq Global Market will be successful, or that the Company's common stock will remain listed on the Nasdaq Global Market; that the Company will complete cost- effective clinical trials or meet as anticipated the development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401, to help generate greater interest in the market for its common stock; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com

'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
2. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
3. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
4. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
6. Keryx Biopharmaceuticals Announces Additions to Management Team
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
10. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
11. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance